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Abstract
Aims: Resting heart rate (HRate) is a modifiable risk factor among patients with cardiovascular disease, 
including aortic stenosis (AS). However, the effect of resting HRate on clinical outcomes of patients with 
severe symptomatic AS undergoing transcatheter aortic valve implantation (TAVI) is unknown. Our aim 
was therefore to assess the effect of resting HRate on clinical outcomes among high-risk patients with symp-
tomatic severe AS in normal sinus rhythm (NSR) undergoing TAVI.
Methods and results: Of 606 consecutive patients undergoing TAVI, 349 (57.6%) with severe AS and 
a baseline 12-lead electrocardiogram (ECG) showing NSR undergoing TAVI were analysed. Patients were 
dichotomised into low HRate (LHR; <77 beats per minute [bpm]) and high HRate (HHR; ≥77 bpm) groups. 
The primary endpoint was all-cause mortality at two years. As compared with baseline LHR, no signifi-
cant differences in all-cause mortality at two years (adjusted [adj] hazard ratio [HR] 1.23, p=0.40) were 
observed among patients with baseline HHR. Of 197 patients with available discharge ECGs remaining in 
NSR, mean HRate significantly increased among LHR patients (∆HRate 8.35, p<0.001) but decreased among 
HHR patients (∆HRate -4.88, p<0.001). On thirty-day landmark analysis, discharge HHR was significantly 
associated with two-year all-cause mortality (HR 2.30, 95% CI: 1.16-4.56, p=0.017), but not after exten-
sive adjustment for comorbidities (adj HR 2.01, 95% CI: 0.98-4.09, p=0.056). A significant interaction for 
two-year mortality (p-interaction 0.021) was observed on landmark analysis for discharge, but not baseline, 
HHR.
Conclusions: Baseline and discharge resting HRate were not associated with adverse outcomes after TAVI.
KEYWORDS
• aortic stenosis
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TAVI and resting heart rate
Introduction
A high resting heart rate (HRate) is a potentially modifiable car-
diovascular risk factor, both in the general population and among 
patients with cardiovascular disease1-3. Large observational studies 
have shown a link between increased HRate and all-cause mortality 
and cardiovascular events in patients with coronary artery disease, 
hypertension, metabolic syndrome and heart failure4-7. A high rest-
ing HRate has recently been shown to be associated with major car-
diovascular events and cardiovascular death among patients with 
asymptomatic aortic stenosis (AS)8. In addition, it was recently 
demonstrated that sympathetic nervous system (SNS) activity is 
increased and arterial baroreflex is impaired in patients with AS 
undergoing transcatheter aortic valve implantation (TAVI)9. A high 
HRate reflects an increase in SNS activity, which may trigger or 
exacerbate many of the pathophysiological features associated 
with AS, such as cardiac hypertrophy and decreased peripheral 
perfusion9. While there have been several studies published to 
date assessing the effect of rhythm disturbances (e.g., atrial fibril-
lation10,11) and conduction abnormalities (e.g., left bundle branch 
block12,13) on clinical outcomes after TAVI, the majority of patients 
remain in normal sinus rhythm after TAVI10,11. Heart rate is an eas-
ily modifiable risk factor and therefore it is clinically useful to 
determine whether or not an elevated heart rate may affect clini-
cal outcomes after TAVI. However, to the best of our knowledge, 
this association has never before been investigated. We therefore 
aimed to assess the effect of resting HRate on clinical outcomes 
among high-risk patients with symptomatic severe AS in normal 
sinus rhythm undergoing TAVI.
Editorial, see page 417
Methods
PATIENT POPULATION
This is a retrospective analysis of prospectively collected data 
from a database that includes all patients with severe native valve 
AS who underwent TAVI at our institution between August 2007 
and December 2012 (n=606). All patients were deemed inoperable 
or at high surgical risk for conventional surgery by a multidisci-
plinary team comprising interventional cardiologists and cardio-
vascular surgeons. Patient flow is shown in Figure 1. Included in 
this study were all consecutive patients with symptomatic severe 
native valve AS in sinus rhythm on 12-lead electrocardiogram 
(ECG) performed ≤30 days prior to TAVI. Exclusion criteria are 
shown in Figure 1. Patients were dichotomised into low (<77 beats 
per minute [bpm]) and high (≥77 bpm) HRate groups according to 
the baseline HRate measured on the pre-procedural 12-lead ECG. 
Discharge 12-lead ECGs were subsequently analysed after TAVI 
to assess the discharge HRate and any changes in HRate occurring 
after TAVI. A cut-off HRate of 77 bpm was chosen based on the 
results of the randomised Systolic Heart failure treatment with the 
If inhibitor ivabradine Trial (SHIFT), where evidence of a signifi-
cant treatment effect with ivabradine was noted only in the sub-
group of patients with baseline heart rates higher than the median 
77 bpm14.
n=97 discharge ECG
normal sinus rhythm
n=349 baseline ECG
normal sinus rhythm
SCREENED POPULATION (consecutive TAVI patients August 2007-December 2012)
STUDY POPULATION
Excluded (n=257)
– missing baseline ECG (n=89)
– greater than 30-day-old ECG (n=26)
– atrial fibrillation (n=96)
– paced rhythm (n=37)
– TAVI in surgical aortic valve bioprosthesis (n=6)
– did not consent to follow-up (n=3)
Excluded (n=152)
– missing discharge ECG (n=87)
– new-onset atrial fibrillation (n=17)
– new permanent pacemaker (n=48)
TAVI
Total n=606
Figure 1. Patient flow for the study population.
The cohort study complies with the Declaration of Helsinki, 
was approved by the local ethics committee, and all patients pro-
vided written informed consent.
ELECTROCARDIOGRAPHY AND ECHOCARDIOGRAPHY
Available 12-lead ECGs were analysed individually by two car-
diologists unaware of clinical data. Discrepancies were resolved 
through consensus. Transthoracic echocardiography was performed 
in all included patients at baseline as previously described15.
CARDIAC CATHETERISATION
All TAVI patients underwent coronary angiography and 290/349 
(83%) had a full invasive evaluation by right and left heart cath-
eterisation prior to TAVI as previously described16.
TRANSCATHETER AORTIC VALVE IMPLANTATION 
PROCEDURE
TAVI was performed as previously described. Vascular access 
was transfemoral using the Medtronic CoreValve Revalving 
System (MCRS) (Medtronic, Minneapolis, MN, USA), Edwards 
SAPIEN/XT (ESV) (Edwards Lifesciences, Irvine, CA, USA) 
or transapical for the latter bioprosthesis or the self-expanding 
Symetis ACURATE TA™ valve (SA) (Symetis Inc., Ecublens, 
Switzerland) or trans-subclavian using the MCRS16.
CLINICAL FOLLOW-UP
Adverse events were assessed in hospital, and regular clinical fol-
low-up was performed at one, six, 12 and 24 months by means of 
a clinical visit or standardised telephone interview. All suspected 
events were adjudicated by an unblinded clinical events commit-
tee, comprising cardiac surgeons and interventional cardiologists 
who were unaware of the heart rate assessments.
STUDY ENDPOINTS
Clinical endpoints were defined according to the criteria proposed 
by the Valve Academic Research Consortium-2 (VARC-2) consen-
sus document17. The primary endpoint was all-cause mortality at two 
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years. The secondary endpoint was cardiovascular death at two years. 
All endpoints were assessed for both baseline and discharge HRate.
STATISTICS
Continuous data are presented as means±standard deviations (SD), 
and categorical variables are shown as percentages and numbers. 
Categorical variables were compared by means of the χ2 test (or 
Fisher’s test for two-group comparisons), and continuous varia-
bles were compared using the unpaired t-test. Time-to-event data 
are presented using Kaplan-Meier curves, with incidence rates 
calculated from life tables at two-year follow-up. Univariate and 
adjusted Cox proportional hazards models were used to derive 
hazard ratio estimates of clinical time-to-event comparisons 
between the two groups. Inverse probability of treatment weighted 
(IPTW) hazard ratios (HR) and 95% confidence intervals (CI) 
were derived from Cox regressions. IPTW values for high ver-
sus low heart rate at baseline, and again separately for heart rate 
at discharge, were calculated using the following baseline clinical 
variables: age, gender, height, body mass index, diabetes, coronary 
artery disease (CAD), multivessel CAD disease, previous myocar-
dial infarction, cardiac surgery, percutaneous coronary interven-
tion, peripheral vascular disease, chronic obstructive pulmonary 
disease (COPD), renal failure, moderate or severe mitral regurgi-
tation, New York Heart Association (NYHA) functional Class III 
or IV (selected if p<0.2 on all-cause death at two years or p<0.2 
on high vs. low). Missing data were replaced with single imputa-
tion (COPD, NYHA III or IV, mitral regurgitation, n=1, 1, and 32, 
respectively). The changes in heart rate from baseline pre-TAVI 
to discharge post-TAVI were analysed with paired t-tests and lin-
ear regression. All p-values and 95% CI are two-sided. Two-sided 
p-values <0.05 were considered statistically significant. All anal-
yses were performed with Stata version 14 (StataCorp, College 
Station, TX, USA).
Results
BASELINE CHARACTERISTICS
Patient characteristics are shown in Table 1. The present analysis 
included 349 patients out of 606 consecutive patients (58%) under-
going TAVI between August 2007 and December 2012 in our insti-
tution. Of the 349 included patients in sinus rhythm prior to TAVI, 
219 (63%) had a low resting HRate (LHR) (defined as <77 bpm) 
and 130 (37%) had a high resting HRate (HHR) (defined as ≥77 
bpm) at baseline before TAVI. As compared with LHR, patients 
with HHR were significantly younger, more likely to be female, 
less likely to have undergone previous cardiac surgery and previ-
ous percutaneous coronary intervention, and were less likely to be 
taking beta-blockers. ECGs were performed at a mean±standard 
deviation of 3.6±5.0 days (range 0-28 days) prior to TAVI. Data 
on periprocedural changes in medications, including beta-blockers 
and calcium channel blockers, are shown in Table 1. We found no 
significant difference in the prevalence of beta-blockers (56% vs. 
57%, p=0.90) or calcium channel blockers (27% vs. 21%, p=0.31) 
prescribed at discharge between low and high heart rate patients.
ELECTROCARDIOGRAPHIC, ECHOCARDIOGRAPHIC AND 
INVASIVE HAEMODYNAMIC CHARACTERISTICS
Baseline electrocardiographic, echocardiographic and invasive 
haemodynamic characteristics are shown in Table 2. As compared 
with LHR, patients with HHR had smaller aortic valve areas, 
worse LV systolic and diastolic function and a higher prevalence 
of moderate to severe mitral regurgitation on baseline echocar-
diography. Patients with HHR also had a more adverse baseline 
haemodynamic profile on pre-procedural right and left heart cath-
eterisation. Interestingly, despite significantly lower stroke volume 
indices among HHR patients, no significant differences in cardiac 
indices were observed between groups. No significant differences 
in pulmonary artery systolic pressures were observed between 
Table 1. Baseline characteristics.
Baseline heart rate
p-value
<77 bpm n=219 ≥77 bpm n=130
Age, years 82.7±5.4 81.5±5.7 0.047
Female gender, n (%) 108 (49%) 83 (64%) 0.010
Past medical history Previous myocardial infarction, n (%) 27 (12%) 20 (15%) 0.42
Previous cardiac surgery, n (%) 41 (19%) 11 (8%) 0.012
Previous coronary artery bypass graft, n (%) 17 (9%) 6 (5%) 0.27
Previous percutaneous coronary intervention, n (%) 68 (31%) 25 (19%) 0.017
Symptoms New York Heart Association (NYHA) functional class
NYHA III/IV, n (%) 144 (66%) 98 (76%) 0.054
Risk assessment Logistic EuroSCORE (%) 20.7±12.0 22.0±14.9 0.39
STS score (%) 6.2±3.8 7.0±5.1 0.09
Medications at baseline Beta-blocker, n (%) 124 (57%) 54 (42%) 0.008
Ca channel blocker, n (%) 50 (23%) 19 (15%) 0.07
Medications at 
discharge
Beta-blocker, n (%) 93 (56%) 58 (57%) 0.90
Ca channel blocker, n (%) 44 (27%) 21 (21%) 0.31
Data expressed as means±SD with p-values from t-tests or counts (%) with p-values from Fisher’s or chi-square tests.
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TAVI and resting heart rate
groups. As expected, HRate measured during right heart catheteri-
sation was significantly higher among HHR patients as compared 
with LHR patients, thereby corroborating the HRate measured on 
baseline ECG.
PROCEDURAL CHARACTERISTICS
Procedural characteristics are shown in Table 3. The majority of 
patients included in the present analysis underwent transfemoral 
TAVI (79%). No significant differences in procedural characteris-
tics were found between groups.
CLINICAL OUTCOMES STRATIFIED ACCORDING TO 
BASELINE HRate
Clinical follow-up was complete for 338/349 (97%) patients (n=9 
lost to follow-up and n=2 refused follow-up). Event rates with 
adjusted hazard ratios (adj HR) and 30-day landmark analyses for 
all-cause mortality and cardiovascular death at two years stratified 
according to baseline HRate are provided in Table 4.
Time-to-event curves for all-cause mortality and cardiovascular 
death at two-year follow-up are shown in Figure 2A and Figure 2B, 
respectively. A 30-day landmark analysis for all-cause mortality 
Table 3. Procedural characteristics.
Baseline heart rate
p-value
<77 bpm n=219 ≥77 bpm n=130
Access route, n (%) 0.81
Transfemoral 172 (79%) 105 (81%) 0.68
Transapical 44 (20%) 24 (18%) 0.78
Trans-subclavian 3 (1%) 1 (1%) 1.00
Valve type, n (%) 0.48
CoreValve 107 (49%) 65 (50%) 0.91
Edwards SAPIEN XT 108 (49%) 60 (46%) 0.58
Symetis 4 (2%) 5 (4%) 0.30
Coronary revascularisation, n (%) 32 (15%) 17 (13%) 0.75
Device success, n (%) 216 (99%) 125 (96%) 0.15
No device success: valve in series 2 (1%) 4 (3%) 0.20
No device success: AR >2 1 (0%) 1 (1%) 1.00
No device success: post-TAVI mean gradient >20 mmHg 0 (0%) 0 (0%)
Post-TAVI need for permanent pacemaker (within 5 days), n (%) 41 (19%) 21 (16%) 0.57
Conversion from local to general anaesthesia, n (%) 4 (4%) 3 (5%) 1.00
Data are expressed as counts (%) with p-values from Fisher’s or chi-square tests.
Table 2. Electrocardiographic, echocardiographic and invasive characteristics.
Baseline heart rate
p-value
<77 bpm n=219 ≥77 bpm n=130
ECG Heart rate (beats/min) 65.58±6.88 88.06±9.03 <0.001
Left bundle branch block, n (%) 17 (8%) 15 (12%) 0.25
Right bundle branch block, n (%) 22 (10%) 10 (8%) 0.57
Echocardiography Aortic valve area (cm2) 0.65±0.23 0.56±0.22 0.002
Aortic maximal velocity (cm.s-1) 4.0±1.0 4.1±0.8 0.51
Mean gradient (mmHg) 45.1±17.6 44.3±17.6 0.72
LV ejection fraction (baseline, %) 55.4±14.0 51.0±17.4 0.016
E/A ratio 1.0±0.7 1.5±1.2 0.041
E-wave deceleration time (ms) 239.6±98.3 182.2±90.3 0.020
Mitral regurgitation 0.003
Moderate 23 (13%) 32 (31%) 0.001
Severe 3 (2%) 3 (3%) 0.67
Invasive 
haemodynamics
Stroke volume index (ml/m²) 30.71±8.21 25.89±7.21 <0.001
Cardiac index (l/min/m²) 2.21±0.49 2.18±0.57 0.67
PA systolic pressure (mmHg) 50.92±17.67 50.71±17.80 0.93
Heart rate (beats/min) 73.55±11.05 86.11±13.82 <0.001
Data are expressed as means±SD with p-values from t-tests or counts (%) with p-values from Fisher’s or chi-square tests. LV: left ventricular; 
PA: pulmonary artery
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and cardiovascular death at two years is shown in Figure 2C and 
Figure 2D, respectively. As compared with baseline LHR, no sig-
nificant differences in all-cause mortality or cardiovascular death 
were observed among patients with baseline HHR at two-year fol-
low-up. On 30-day landmark analysis, no significant differences in 
all-cause mortality or cardiovascular death were observed among 
patients with baseline HHR on unadjusted or adjusted analysis at 
two-year follow-up (Table 4, Figure 2C, Figure 2D).
No significant interaction was observed between overall mor-
tality (p-interaction 0.91) and cardiovascular death (p-interaction 
0.44) event rates occurring before and after 30-day follow-up 
(Figure 2C, Figure 2D).
CHANGES IN HRate AFTER TAVI
Changes in resting HRate measured on 12-lead ECGs before and 
after TAVI among patients remaining in normal sinus rhythm on 
discharge ECG (n=197) are shown in Table 5 and Figure 3. Overall, 
the mean HRate increased after TAVI on discharge ECG. Among 
LHR patients, the mean HRate significantly increased following 
TAVI on discharge as compared with baseline ECG. Conversely, 
Table 4. Adjusted clinical outcomes at 2-year follow-up stratified by baseline resting heart rate.
Baseline heart rate <77 vs. ≥77
p-value
<77 bpm n=219 ≥77 bpm n=130 HR (95% CI)
2-year follow-up All-cause death, n (%) 48 (23.5) 38 (32.0) 1.23 (0.77-1.96) 0.40
Cardiovascular death, n (%) 31 (15.6) 24 (20.8) 1.15 (0.64-2.07) 0.64
Landmark 
30 days to 2 years
All-cause death, n (%) 38 (19.4) 30 (26.6) 1.25 (0.73-2.12) 0.41
Cardiovascular death, n (%) 24 (12.5) 16 (15.0) 1.03 (0.51-2.08) 0.95
Depicted are number of events (incidence rates from life tables, %). Inverse probability of treatment weighted (IPTW) hazard ratios (HR [95% 
confidence intervals]) from Cox regressions. IPTW for high versus low heart rate calculated using the following baseline clinical variables: age, gender, 
height, body mass index, diabetes mellitus, coronary artery disease, multivessel disease, previous myocardial infarction, cardiac surgery, percutaneous 
coronary intervention, peripheral vascular disease, chronic obstructive pulmonary disease (COPD), renal failure, moderate or severe mitral regurgitation, 
New York Heart Association (NYHA) functional Class III or IV (selected if p<0.2 on all-cause death at two years or p<0.2 on high versus low). Missing 
data replaced with single imputation (COPD, NYHA II or IV, mitral regurgitation). 
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Number at risk
Low heart rate 219 200 191 186 156 146 128
High heart rate 130 115 110 101   82   73   63
Number at risk
Low heart rate 219 200 191 186 156 146 128
High heart rate 130 115 110 101   82   73   63
Figure 2. Clinical outcomes according to baseline heart rate. Kaplan-Meier analysis of death (A) and cardiovascular death (B) at two years 
among patients undergoing transcatheter aortic valve implantation (TAVI) stratified according to low (heart rate <77 beats per minute [bpm]) 
versus high (heart rate ≥77 bpm) baseline resting heart rate. Thirty-day landmark analysis of death (C) and cardiovascular death (D) at two 
years among patients undergoing TAVI stratified according to low versus high resting heart rate at baseline.
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TAVI and resting heart rate
among HHR patients, the mean HRate significantly decreased after 
TAVI on discharge as compared with baseline ECG.
CLINICAL OUTCOMES STRATIFIED ACCORDING TO 
DISCHARGE HRate
Event rates with adj HRs for all-cause mortality and cardiovas-
cular death and 30-day landmark analyses at two years stratified 
n=19760
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Figure 3. Scatter plot showing the changes in heart rate before and 
after transcatheter aortic valve implantation (TAVI) among patients 
remaining in normal sinus rhythm as measured on the baseline and 
discharge 12-lead electrocardiograms (n=197 patients), respectively. 
The resting heart rate at baseline on the x-axis is plotted against the 
change in heart rate (delta heart rate) after TAVI, i.e., discharge 
heart rate minus baseline heart rate, on the y-axis.
Table 5. Change in heart rate after transcatheter aortic valve implantation among patients remaining in sinus rhythm.
Heart rate Difference (95% CI 
discharge – baseline)
p-value
Baseline Discharge
All patients (N=197) 73.9±13.4 77.3±11.5 3.38 (1.54 to 5.22) <0.001
HR <77 bpm (N=123) 65.5±6.9 73.8±10.6 8.35 (6.26 to 10.44) <0.001
HR ≥77 bpm (N=74) 88.0±8.9 83.1±10.6 –4.88 (–7.37 to –2.39) <0.001
Data are expressed as means with standard deviation, p-values from paired t-tests. Only includes patients who had both a baseline and a discharge 
heart rate measurement showing normal sinus rhythm only. Included patients missing discharge 12-lead electrocardiograms (n=87), showing new-onset 
atrial fibrillation (n=17) or a paced rhythm (n=48) were excluded from this analysis.
according to discharge HRate are provided in Table 6. Time-to-
event curves for all-cause mortality and cardiovascular death at 
two-year follow-up stratified according to discharge HRate are 
shown in Figure 4A and Figure 4B, respectively. A landmark anal-
ysis at 30 days for all-cause mortality and cardiovascular death at 
two years is shown in Figure 4C and Figure 4D, respectively.
As compared with discharge LHR, no significant differences in 
all-cause mortality or cardiovascular mortality among discharge 
HHR patients were observed. On 30-day landmark analysis, dis-
charge HHR was significantly associated with all-cause mortal-
ity at two-year follow-up (HR 2.30, 95% CI: 1.16-4.56, p=0.017) 
although this significance was lost after extensive adjustment for 
comorbidities (adj HR 2.01, 95% CI: 0.98-4.09, p=0.056). A sta-
tistically significant interaction was observed for overall mortal-
ity (p-interaction 0.021) and cardiovascular death (p-interaction 
0.031) events occurring before and after 30-day follow-up (Figure 
4C, Figure 4D) for discharge HRate.
Discussion
The main finding from the present study was that neither baseline 
nor discharge HHR was associated with overall or cardiovascular 
mortality two years after TAVI. Although patients with HHR had 
worse echocardiographic and invasive haemodynamic profiles at 
baseline as compared with LHR patients, this did not translate into 
worse clinical outcomes at two-year follow-up. A novel observa-
tion was that TAVI resulted in a significant physiological mod-
ification of the resting HRate, i.e., the majority of LHR patients 
had a significant increase in resting HRate, whereas the majority 
of HHR patients exhibited a significant decrease in resting HRate 
Table 6. Adjusted clinical outcomes at 2-year follow-up stratified by discharge resting heart rate (normal sinus rhythm).
Discharge heart rate <77 vs ≥77
p-value
<77 bpm n=100 ≥77 bpm n=97 HR (95% CI)
2-year follow-up All-cause death, n (%) 18 (19.8) 28 (30.9) 1.43 (0.77-2.65) 0.25
Cardiovascular death, n (%) 13 (14.2) 17 (19.6) 1.14 (0.54-2.39) 0.74
Landmark 
30 days to 2 years
All-cause death, n (%) 12 (14.7) 26 (29.5) 2.01 (0.98-4.09) 0.056
Cardiovascular death, n (%) 7 (8.7) 15 (17.9) 1.80 (0.71-4.58) 0.21
Depicted are number of events (incidence rates from life tables, %). Inverse probability of treatment weighted (IPTW) hazard ratios (HR [95% 
confidence intervals]) from Cox regressions. IPTW for high versus low heart rate calculated using the following baseline clinical variables: age, gender, 
height, body mass index, diabetes mellitus, coronary artery disease, multivessel disease, previous myocardial infarction, cardiac surgery, percutaneous 
coronary intervention, peripheral vascular disease, chronic obstructive pulmonary disease (COPD), renal failure, moderate or severe mitral regurgitation, 
New York Heart Association (NYHA) functional Class III or IV (selected if p<0.2 on all-cause death at two years or p<0.2 on high versus low). Missing 
data replaced with single imputation (COPD, NYHA II or IV, mitral regurgitation). 
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after TAVI (Figure 3). The latter observation may explain the lack 
of effect of baseline resting HRate on clinical outcomes after TAVI. 
In contrast to baseline HRate, a discharge HHR was significantly 
associated with overall mortality two years after TAVI on 30-day 
landmark analysis, although this significance was lost after exten-
sive adjustment (HR 2.01, 95% CI: 0.98-4.09, p=0.056).
RELATIONSHIP BETWEEN RESTING HRate AND OUTCOMES 
IN CARDIOVASCULAR DISEASE
A significant association between resting HRate and mortal-
ity has been reported among patients with a variety of cardio-
vascular diseases, including acute coronary syndromes18, and 
hypertension19. Furthermore, HRate was found to be directly 
related to the risk of death, cardiovascular death, or admission 
to hospital in patients with heart failure20, and HRate reduction 
was found to be associated with improved outcomes21. Resting 
HRate is included in several risk assessment algorithms for 
patients after acute coronary syndromes, such as the Global 
Registry of Acute Coronary Events risk prediction (GRACE) 
score and the Thrombolysis In Myocardial Infarction (TIMI) 
risk score22,23. Ivabradine is a selective inhibitor of the funny 
current (If), which results in HRate reduction with no other 
apparent direct cardiovascular effects24. In the Ivabradine for 
patients with stable coronary artery disease and left-ventricular 
systolic dysfunction (BEAUTIFUL) trial, ivabradine-induced 
HRate reduction did not affect the primary composite endpoint 
of cardiovascular death, hospital admission for acute myocar-
dial infarction, and hospital admission for new-onset or wors-
ening heart failure24. However, it did reduce the secondary 
endpoints of hospital admission for fatal and non-fatal myo-
cardial infarction and coronary revascularisation. Furthermore, 
a subanalysis of the BEAUTIFUL trial revealed that an HRate 
of ≥70 bpm was associated with a 34% increased risk of car-
diovascular death, a 53% increase in admission to hospital for 
heart failure, and a 46% increase for admission to hospital for 
myocardial infarction compared with HRate lower than 70 bpm, 
even after adjustment for other predictors of outcomes7. In the 
Systolic Heart failure treatment with the If inhibitor ivabradine 
Trial (SHIFT), comprising patients in sinus rhythm with a rest-
ing HRate ≥70 bpm (in contrast to the 60 bpm cut-off used in 
the BEAUTIFUL trial) and LVEF ≤35%, ivabradine was asso-
ciated with an 18% relative risk reduction in the composite pri-
mary endpoint of cardiovascular death or hospital admission 
for worsening heart failure (p<0.0001)14.
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Figure 4. Clinical outcomes according to discharge heart rate. Kaplan-Meier analysis of death (A) and cardiovascular death (B) at two years 
among patients undergoing transcatheter aortic valve implantation (TAVI) stratified according to low (heart rate <77 beats per minute [bpm]) 
versus high (heart rate ≥77 bpm) discharge resting heart rate. Thirty-day landmark analysis of death (C) and cardiovascular death (D) at two 
years among patients undergoing TAVI stratified according to low versus high resting heart rate at discharge.
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TAVI and resting heart rate
RELATIONSHIP BETWEEN RESTING HRate AND OUTCOMES 
IN PATIENTS WITH AS
Among patients with asymptomatic AS, recent studies have also 
shown resting HRate to be an independent predictor of cardiovas-
cular mortality8. In a subanalysis of the Simvastatin Ezetimibe 
in Aortic Stenosis (SEAS) study, Greve et al assessed the prog-
nostic value of an elevated resting HRate during watchful wait-
ing in asymptomatic AS8. An elevated resting HRate was observed 
to be independently associated with major cardiovascular events 
and cardiovascular death during long-term follow-up even after 
adjusting for other predictors of outcomes8. Dumonteil et al 
recently demonstrated that TAVI normalises SNS overactivity9. 
The investigators directly measured muscle sympathetic nerve 
activity and arterial baroreflex gain in 14 patients with severe 
symptomatic AS before and a week after TAVI and in 14 con-
trol patients without AS9. They found that patients with AS had 
increased SNS activity associated with a decrease in sympathetic 
arterial baroreflex gain compared with controls, and that TAVI 
normalised these parameters9. In the present study, the normalisa-
tion of sympathetic overactivity may explain the significant HRate 
reduction observed among HHR patients after TAVI. This may 
ultimately explain the lack of differences in clinical outcomes 
observed between patients with HHR and LHR after TAVI. We 
observed that HHR patients had significantly lower stroke vol-
umes and stroke volume indices on right heart catheterisation as 
compared with LHR patients. It is likely that this low flow state 
leads to activation of the SNS leading to an increase in HRate in an 
effort to compensate for the low stroke volume. We also observed 
that patients with LHR had a significant increase in HRate after 
TAVI. The reason for this is unclear. Further studies correlating 
changes in heart rate after TAVI with post-procedural changes in 
cardiac output and stroke volume are required in order to explain 
this phenomenon.
Limitations
There are a number of limitations that need to be considered when 
interpreting this study. First, the present study was a single-centre 
retrospective study. Even though all data were prospectively col-
lected and all events adjudicated by an independent clinical events 
committee, our results may contain unmeasured bias. Second, the 
sample size is relatively small (n=349), and only 197 patients 
had available data for discharge analysis. However, to the best of 
our knowledge, this is the first study to question the association 
between resting sinus rhythm HRate and clinical outcomes in TAVI 
patients. Third, this is not a consecutive patient series, as patients 
with missing ECGs or those who received ECGs >30 days prior 
to TAVI were excluded. Furthermore, not all included patients had 
discharge ECGs available. Finally, there are other factors that can 
influence resting HRate apart from SNS activity.
Conclusions
Neither baseline nor discharge resting HHR was associated with 
all-cause mortality or cardiovascular death after TAVI.
Impact on daily practice
Resting sinus rhythm heart rate is known to be a modifiable 
risk factor for cardiovascular disease, including aortic steno-
sis. However, there have been no studies to date assessing the 
effect of baseline and discharge resting sinus rhythm heart rate 
on clinical outcomes after transcatheter aortic valve implanta-
tion (TAVI). We observed that resting sinus rhythm heart rate 
at baseline and discharge had no effect on two-year mortality 
rates after TAVI. 
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